HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons

The review analyzes the potential advantages and problems associated with using HIF prolyl hydroxylase inhibitors as a treatment for COVID-19. HIF prolyl hydroxylase inhibitors are known to boost endogenous erythropoietin (Epo) and activate erythropoiesis by stabilizing and activating the hypoxia in...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Front Pharmacol
Autori principali: Poloznikov, Andrey A., Nersisyan, Stepan A., Hushpulian, Dmitry M., Kazakov, Eliot H., Tonevitsky, Alexander G., Kazakov, Sergey V., Vechorko, Valery I., Nikulin, Sergey V., Makarova, Julia A., Gazaryan, Irina G.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Frontiers Media S.A. 2021
Soggetti:
Pharmacology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7878396/
https://ncbi.nlm.nih.gov/pubmed/33584306
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.621054
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi